Okay. And then just on the New York State program, I understand that that's on hold and no surprise there, I guess. But just thinking about it in Q1, will there be or was there any revenue recognized during the quarter for that program?
Yes, Ben, that's a good question. If you remember, there was one final milestone in the first year, I'll let Evan touch on maybe potential out-year. But we will be recognizing that last piece of the final milestone in Q1.
Okay. And back to the programmatic side of this, the full system was up and running, including the real-time evaluation of patient records, our AMR-pathogen detection showing some very promising data. And certainly, as you can imagine, the New York Metro Area being at the foci of the COVID situation, it's all hands on deck for that with -- in terms of resources. But one of the things that this has shown is that the whole infrastructure and capability may be repurposed in interesting ways to help the state as they go to phase 2 of this. Meaning, after we get past this initial surge, how do we manage COVID-19 patients through the rest of this year and beyond? And as things potentially develop there, we'll keep you posted.
Okay. So that kind of flows into my final question. Just thinking about the Lighthouse and the pathogen tracking that you're already doing on the bacterial side, is that something that could be expanded to track viruses as well? And if so, what are the -- what are you guys doing there?
So I'll answer this, and then hand it over to Oliver if he wants to add anything. Clearly, opportunities there, Ben. I think the -- we just don't want to get ahead of things. And if there's more to describe, we will bring it forward in the coming month or 2.
I would just add, I mean, obviously, with the Lighthouse on the OpGen side and the RSDB in Austria with Ares Genetics, technologically, a nucleic acid is a sequence of individual letters, whether it's a DNA or an RNA, a bacteria or a virus, to the software, to the algorithms per se is neither here nor there. So is it technically doable? The answer is clearly yes. In many ways, a single virus is a much simpler beast than having dozens of different bacteria that also get resistant. But again, as Evan said, we haven't made any final decisions at this point on how to best approach this, not just from a technical development standpoint but also from a collaborative standpoint with New York State or other potential laboratory partners in the U.S. and/or Europe. So we'll update folks as we move forward.
My first one is just, I understand that the testing landscape for COVID-19 is rather fluid. But I was wondering if you give us a sense of where the Curetis COVID-19 test stands compared to others that are available in Europe?
Market Data 
Markets 
